500,000 patients’ data for sale online after UK Biobank breach
Last week, data from 500,000 participants of UK Biobank’s database were made available for sale online following a breach, the …
Post
-
-
Sanofi receives FDA approval for Tzield in paediatric diabetes
Sanofi has received approval from the US Food and Drug Administration (FDA) for a supplemental biologic licence application for Tzield …
-
AbbVie opts for North Carolina to house $1.4bn manufacturing site
AbbVie has tapped North Carolina as the location for a new $1.4bn manufacturing site as part of its $100bn US …
-
Operational Lessons from Global Nephrology Trials
From novel drug targets for chronic kidney disease (CKD)[i] to advances in multifunctional drugs promising better efficacy, recent developments in …
-
MSD teams up with Google Cloud on agentic AI transformation
Merck & Co (MSD) and Google Cloud have formed a multi-year partnership, investing up to $1bn, to advance agentic AI …
-
AbbVie opts for North Carolina to house $1.4bn manufacturing site
AbbVie has tapped North Carolina as the location for a new $1.4bn manufacturing site as part of its $100bn US …
-
Operational Lessons from Global Nephrology Trials
From novel drug targets for chronic kidney disease (CKD)[i] to advances in multifunctional drugs promising better efficacy, recent developments in …
-
MSD teams up with Google Cloud on agentic AI transformation
Merck & Co (MSD) and Google Cloud have formed a multi-year partnership, investing up to $1bn, to advance agentic AI …
-
Medicare weight loss drug pilot on ice as insurers decline to contribute
The Centers for Medicare & Medicaid Services (CMS) has hit pause on its pilot programme designed to offer insurer-fronted access …
-
Immunotherapy in locally advanced HNSCC: is there still room for new agents?
The treatment landscape for locally advanced head and neck squamous cell carcinoma (LA HNSCC) has changed significantly. In June 2025, …
-
MSD-backed Ray locks in $125m to back eye drug pipeline
Ray Therapeutics has secured $125m in a Series B funding round, as the gene therapy-focused biopharma eyes a breakout on …
-
FDA approves MSD’s once-daily HIV combo Idvynso
MSD (Merck & Co) has secured a US approval for its two-drug human immunodeficiency virus (HIV) combination therapy, Idvynso (doravirine/islatravir), …
-
BioAegis and Prenosis partner for inflammatory disease therapies
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases. The collaboration will evaluate …
-
The definitive infrastructure for modern drug development
Paradigm Health delivers a unified, AI-powered clinical research platform embedded within a national network of community and academic sites. By …
-
Health Canada approves Biocon’s two denosumab biosimilars
Biocon has received a Notice of Compliance from Health Canada for Bosaya (denosumab) and Vevzuo (denosumab), both biosimilars referencing Prolia …
